Agios Pharmaceuticals, Inc. (AGIO) vs Hemab Therapeutics Holdings, Inc. (COAG)

Agios Pharmaceuticals, Inc. and Hemab Therapeutics Holdings, Inc. are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Hemab Therapeutics Holdings, Inc. are of similar size ($1.9B and $1.8B). Hemab Therapeutics Holdings, Inc. has the higher net margin (0.00% vs −264.8%) and the higher return on invested capital (0.00% vs −75.0%). Across the 10 metrics below, Hemab Therapeutics Holdings, Inc. leads on 8 and Agios Pharmaceuticals, Inc. on 2.

Valuation

Metric AGIO COAG Biotechnology median
P/E n/m n/m 11.36
P/S 13.43 n/m 9.12
P/B 1.93 4.47 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 8.95 n/m 8.56
Earnings yield (19.95%) (105.55%) (34.18%)
Free cash flow yield (17.77%) (4.64%) (23.62%)

Profitability

Metric AGIO COAG Biotechnology median
Gross margin 93.81% — 67.24%
Operating margin (297.72%) 0.00% 0.00%
Net margin (264.76%) 0.00% 0.00%
Free cash flow margin (238.54%) 0.00% 0.00%
Return on equity (32.95%) 0.00% (50.28%)
Return on assets (30.44%) 0.00% (45.89%)
Return on invested capital (75.02%) 0.00% 0.00%

Growth

Metric AGIO COAG Biotechnology median
Revenue growth (TTM) 214.44% — 6.96%
EPS growth (last fiscal year) (161.17%) — 29.86%
Revenue growth, 5-year CAGR (14.45%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AGIO COAG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.69 33.86 4.72
Net debt to EBITDA 1.80 — 1.01

Dividend

Metric AGIO COAG Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AGIO COAG Biotechnology median
Market cap 1.90b 1.84b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack